Status:
COMPLETED
Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015
Lead Sponsor:
Alligator Bioscience AB
Conditions:
Solid Tumor
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The aim of the study is to investigate the safety and tolerability of ATOR-1015 when administered as repeated intravenous infusions to patients with advanced and/or refractory solid malignancies.
Eligibility Criteria
Inclusion
- Major
- Diagnosis of advanced and/or refractory solid malignancy
- Eastern Cooperation Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of at least 3 months
- Major
Exclusion
- Organ transplant recipient
- Active autoimmune disorder
- Other malignancy
Key Trial Info
Start Date :
January 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 3 2021
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT03782467
Start Date
January 30 2019
End Date
March 3 2021
Last Update
August 18 2022
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Phase 1 Unit, Department of Oncology, Rigshospitalet
Copenhagen, Denmark, DK-2100
2
Center for Cancer Research, Department of Oncology, Herlev Hospital
Herlev, Denmark, DK-2730
3
Kliniska Prövningsenheten, Kliniska Studier Sverige - Forum Söder, Skånes Universitetssjukhus
Lund, Sweden, SE-221 85
4
Centrum för Kliniska Cancerstudier (CKC), Fas 1-enheten, Karolinska Universitetssjukhuset
Solna, Sweden, SE-171 64